Cybin (HELP) Net Income towards Common Stockholders (2020 - 2024)
Cybin's (HELP) quarterly Net Income towards Common Stockholders came in at -$0.02 in Q2 2024, up 61.62% YoY from -$0.01 in Q3 2023, and up 69.75% on a QoQ basis from -$0.07 in Q4 2023.
Cybin (HELP) Net Income towards Common Stockholders (2020 - 2024) Analysis & Trends
Cybin (HELP) has 5 years of Net Income towards Common Stockholders data on file, last reported at -$0.02 in Q2 2024.
- Quarterly Net Income towards Common Stockholders rose 61.62% year-over-year to -$0.02 in Q2 2024, while the trailing twelve-month figure through Mar 2025 was -$0.02 (up 87.14% YoY) and the FY2026 annual result came in at -$147.8 million, down 53.91% from the prior year.
- Net Income towards Common Stockholders climbed to -$0.02 in Q2 2024, from -$0.07 in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $4.6 million in Q2 2022 to a low of -$0.1 in Q1 2022.
- A 5-year average of $303494.0 and a median of -$0.05 in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders sank 191.12% — and 2024, when it jumped 61.62%.
- Tracing HELP's Net Income towards Common Stockholders over 5 years: stood at -$0.08 in 2020, then slipped by 3.43% to -$0.08 in 2021, then soared by 44.28% to -$0.04 in 2022, then tumbled by 49.56% to -$0.07 in 2023, then soared by 69.75% to -$0.02 in 2024.
- The last three Net Income towards Common Stockholders figures came in at -$0.02 (Q2 2024), -$0.07 (Q4 2023), and -$0.04 (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Cybin | 417.29 Mn | 417.29 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | -0.02 |
| Dec 31, 2023 | -0.07 |
| Sep 30, 2023 | -0.04 |
| Jun 30, 2023 | -0.05 |
| Dec 31, 2022 | -0.04 |
| Sep 30, 2022 | -0.05 |
| May 31, 2022 | 4.55 Mn |
| Mar 31, 2022 | -0.10 |
| Dec 31, 2021 | -0.08 |
| Sep 30, 2021 | -0.09 |
| Jun 30, 2021 | -0.07 |
| Mar 31, 2021 | -0.09 |
| Dec 31, 2020 | -0.08 |
| Sep 30, 2020 | -0.03 |
| Jun 30, 2020 | -0.05 |